Compare PKE & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKE | VNDA |
|---|---|---|
| Founded | 1954 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.4M | 361.4M |
| IPO Year | 1994 | 2005 |
| Metric | PKE | VNDA |
|---|---|---|
| Price | $31.60 | $5.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.90 |
| AVG Volume (30 Days) | 196.0K | ★ 715.2K |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | ★ 93.10 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | N/A | $21.35 |
| Revenue Next Year | N/A | $37.40 |
| P/E Ratio | $185.18 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $18.19 | $4.27 |
| 52 Week High | $39.86 | $9.91 |
| Indicator | PKE | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 35.91 | 40.31 |
| Support Level | $30.47 | $4.94 |
| Resistance Level | $35.94 | $5.55 |
| Average True Range (ATR) | 1.18 | 0.19 |
| MACD | -0.22 | -0.01 |
| Stochastic Oscillator | 6.57 | 4.76 |
Park Aerospace Corp is an aerospace company that develops and manufactures composite materials used to produce composite structures for the aerospace market. Its products include film adhesives, lightning strike protection materials, specialty ablative materials for rocket motors and nozzles, and materials for radome applications. The Company offers composite materials designed for hand lay-up and automated fiber placement (AFP) manufacturing applications, which are used in jet engines, large and regional transport aircraft, military aircraft, unmanned aerial vehicles (UAVs), business jets, general aviation aircraft, and rotary wing aircraft. It operates in North America, Asia, and Europe, with North America generating maximum revenue.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.